key: cord-0860536-m127cqle
authors: Liu, Binjian; Su, Xibin; Yu, George; Yang, Shuling; Wang, Feng; Huang, Tao; Zhou, Liuyong; Hui, Zhiqiang; Liao, Yixian; Qiu, Yuan; Huang, Juan; Gao, Hong; Liu, Justin; Zhong, Yaoqi
title: An automated chemiluminescent immunoassay (CLIA) detects SARS-CoV-2 Neutralizing antibody levels in COVID-19 patients and vaccinees
date: 2021-12-10
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.12.316
sha: 9212d8decaf467b61eb7a7f28d088e964e58ef6b
doc_id: 860536
cord_uid: m127cqle

Objectives To detect neutralizing antibody levels, a specific and sensitive automated chemiluminescent immunoassay (CLIA) was developed. This method can be used for SARS-COV-2 diagnosis, treatment and vaccine evaluation. Methods SARS-CoV-2 receptor-binding domain (RBD) and a stabilized version of the spike (S) ectodomain as antigens were detected by CLIA. Sera neutralizing antibody (NAb) titers and concentrations from 860 SARS-COV-2 vaccinees, 232 SARS-COV-2 convalescent individuals and 675 healthy individuals had been tested by micro neutralization test (MNT) and CLIA respectively. Mathematical methods were established to evaluate the relationship between two variables in different groups. Results Analyzing the relationship between NAb titers and concentration, the R-squares of Decision-making tree was 0.870 and that of Progressive linear fitting was 0.821. The ROC curves indicated specificity (78.1%), sensitivity (87.4%), cutoff value (6.43 AU/mL) and borderline (5.79-7.07 AU/mL) of CLIA. 75.4% vaccinees were detected NAb positive, and 5.35% vaccinees got NAb protective capability. The half-life period of NAb in vaccinees was 10-11weeks. Conclusions With the described RBD-based CLIA protocol, the CLIA can be used to replace MNT in testing SARS-COV-2 NAb. The effectiveness, protectiveness and durability of vaccine can be evaluated effectively by mathmatical models. It is necessary for vaccinees to take NAb assay periodically.

The ongoing coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infections, has resulted in a devastating global pandemic. Nucleic acid tests (NATs) of SARS-COV-2 is the golden standard for clinical diagnostic methods of COVID-19 detection (WHO, 2021) .

Serology assays can play a supplementary but indispensable role in: (1) diagnosis of suspected cases with negative viral RNA test or past (2) monitoring immune responses to assess the course, degree, and durability of immunity; (3) identifying potential convalescent plasma donors; (4) therapeutic antibody development and evaluation; (5) vaccine development and evaluation (Guoqiang and James, 2021) .The neutralizing antibody (NAb), a pivotal immune product for protection and treatment against the virus, arouses a particular interest in medical researchers. However, the internal mechanism between the NAb titers and its protective and therapeutic functions still remains unknown. The virus neutralizing assay, the golden standard in the test of NAb titers, has lots of restrictions, including complicated laboratory requirements, long time period and rigorous operation standards (Gauger and Vincent, 2020) . Most importantly, it must be performed in biosafety level 3 (BSL-3) containment. These restrictions would increase the difficulties to get the data of NAb titers, and therefore making it hard to apply in the clinical routine inspection. With the occurrence of SARS-COV-2 vaccine, the evaluation of vaccine protection becomes crucial. We hope to explore a convenient method to evaluate the sustained protective effects in the people who have accepted vaccine and the therapeutic effects in the convalescent patients.

Currently, lots of studies have discovered the functions of NAb in the treatments of convalescent plasma. Wu et al show the titers of NAb in all patients were low before 10 days from symptom onset (fso) and then increased at 10 to 15 days fso, remaining stable thereafter (Wu et al., 2020) . 30% of convalescent patients generated very low titers of NAb. Ye M et al and Shen C et al have reported the successful application of convalescent plasma in the treatments of SARS-COV-2 patients (Shen et al., 2020; Ye et al., 2020) . With the spread of the epidemic, more and more researches have explored the mechanism and application of NAb.

Here, we set out to develop automated chemiluminescent immunoassay (CLIA) method to measure NAb concentration, and use micro neutralization test (MNT) to measure NAb titers in convalescent patients and healthy people who accepted vaccine (Manenti et al., 2020) . Herein, we aim to build mathematical models to explain the relationship between NAb titers and concentration, and compare the NAb titers attribution between vaccinees and convalescent patients. The study results may provide significant information in the effectiveness of vaccine and the protection of convalescent patients' plasma.

The retrospective study included 1767 participants. The participants consist of 232 convalescent patients, 675 healthy people, and 860 vaccinees who had been injected with SARS-COV-2 vaccine twice. The data in convalescent group and partial data in vaccine group were collected from Feb 1 st 2020 to Apr 1 st 2021 in the hospital of China. The data in healthy group and the rest of data in vaccine group were collected from Jan 1 st 2020 to Apr 1 st 2021 through volunteer recruitment.

All the convalescent patients and SARS-COV-2 vaccinees signed informed consents.

The convalescent patients had been diagnosed with COVID-19 and the plasma were collected after recovery. The individuals had received SARS-COV-2 vaccine twice, and the plasma were collected dozens of days after vaccination.

In order to establish the cutoff value and borderline for NAb CLIA test, 675 SARS-CoV-2 negative sera collected before the current SARS-CoV-2 pandemic were measured. The mean of the NAb Arbitrary Unit plus six standard deviations (SD) was used to define the cutoff value, and the borderline is ±10% cutoff (Peterhoff et al., 2021) . The cutoff value and borderline were validated by ROC curves. Therefore, the cohorts' NAb baselines about SARS-CoV-2 negative people, vaccinated people and symptom onset people could be determined.

The SARS-COV-2 virus 20SF014/vero-E6/3 was isolated from a SARS-COV-2 patient in Shenzhen in February 2020. The SARS-COV-2 virus 20SF18530/vero-E6/3 was 

The virus stock was titrated by serial dilute by 10-fold. Cytopathic effect (CPE) was observed under microscope 7 days after inoculation. The endpoint dilution leading to CPE in 50% of inoculated wells was designated as one 50% tissue culture infecting dose (TCID50) (Reed, 1938) . Serial four-fold dilution of heat-inactivated sera was made. The serum dilutions 240 μL were mixed with equal volumes of 120 μL TCID50 of SARS-CoV-2 as indicated. After 2 h of incubation, 100 μL of the virus-serum mixture was added in quadruplicate to Vero E6 cell mono layers in 96-well microtiter plates. Then, an additional 100 μL of culture medium was added to each well and the plates incubated for 7 days. A serial 10-fold dilution of the virus: 100 μL TCID50/50 8 μL, 10 μL TCID50/50 μL, 1 μL TCID50/50 μL and 0.1 TCID50/50 μL was made as control and loading into 8 wells of 96-well microtiter plates with additional 100μL of culture medium.

The CPE was read at 7 days post infection. The highest serum dilution that completely protected the cells from CPE in half of the wells was taken as the neutralizing antibody (NAb) titer. More than 4 times dilution could protect the cells from virus infection was set as the cutoff of the positive.

An automated chemiluminescent immunoassay (CLIA) method was developed to detect SAR-CoV-2 neutralizing antibodies concentration by using Immu F6 Automatic Chemiluminescent Immunoassay Analyzer (Shenzhen Medcaptain Medical Technology Co., Ltd.,). The assay took the format of competition chemiluminescent immunoassay. RBD domain in S protein of SAR-CoV-2 were combined with magnetic microparticle. Upon mixing the sample with reaction diluent, the neutralizing antibodies would combine with RBD domain in S protein. The remained uncombined RBD domain in S protein of SAR-CoV-2 were collected and reacted with ACE2 which labeled by acridinium ester (AE). The concentration of neutralizing antibodies was inversely proportional to chemiluminescence data. The reagents were manufactured by Shenzhen Medcaptain Medical Technology Co., Ltd. Calibration and Control 9 testing were done in accordance with the instruction of users (IFU). The test operation procedures were done strictly according to the IFU.

The titers and concentration of NAb were non-linear related. The appropriate methods for parameters simulation to identify the relationship between the titers and concentration of NAb were strongly needed (Parmar et al., 2015) . The mathematical models which demonstrated it were established according to the flow chart thereafter (see supplementary material).

The statistical analysis was conducted in MedCalc version 18.2 and Orange data mining version 2.8.2. Medians were used in general descriptions. Different statistical methods were used as needed.

In total, 232 convalescent patients, 860 vaccinees and 675 healthy people were analyzed in this study ( Table 1) . 59 participants in convalescent group were used to observe the NAb variation from symptom onset to 6 months later. 

Healthy group, Vaccine group and Convalescent group had different NAb concentration distributions. There were significant differences among three groups (P<0.01) (Figure 1a) . Both in vaccine group and convalescent group, the NAb concentrations and NAb titers were strongly positive related (P<0.001) (Figure 1b,   1c ). 

According to the report by Peterhoff, the cutoff value of NAb concentration of healthy people was 6.277 AU/mL, and the borderline ranged from 5.73 to 7.22 AU/mL (Peterhoff et al., 2021) . The ROC curve of NAb concentration of vaccinees and convalescent patients had been done to validate it. The ROC curve showed that the cutoff value was 6.43 AU/mL, and the borderline ranged from 5.79 to 7.07 AU/mL ( Figure 2 ). Decision-making tree model 15 The outcome using decision-making tree was shown in Figure 3 . The outcome of model verification

Using two different methods to find out the cutoff value and borderline, as described above, the specificity of our assay was determined by measuring 675 independent SARS-CoV-2 infection negative sera. The false positive rate was 2 out of 675 sera, corresponding to a specificity of 99.7%.

Both progressive linear fitting model and decision-making tree model had the same results in verification. There were 95.7% points in the 95% limits of agreement. Two models had good consistency with gold standard. (Figure 5 .) 

In vaccine group, both NAb titers and NAb concentrations had same distribution tendencies in age and gender. The NAb concentrations in age groups of 19-50 years old were higher than those in other age groups. It implied that immune response in adults was stronger than that in elders. There were significant differences between male and female in the same age group (P<0.01). The immune response in female was stronger than that in male ( 

In convalescent group, the NAb increased rapidly several days after symptom onset, and declined over time. The half-life period of NAb in convalescent people was 5.7947 months. When the NAb concentration was lower than 64 AU/mL, the convalescent patients (97% CI) did not have protective capability (titers＜1:160). The age (95% CI) of convalescent people whose NAb had protective capability was 30 to 75 years old. (Figure 8 .) severe, mild, and asymptomatic COVID-19 manifestations will need to be factored into calculating prevalence based on serosurveys (Krammer and Simon, 2020) .

Neutralizing antibody (NAb) is a protective antibody which blocks S-protein to conjugate ACE2 on alveolar epithelial cells (Datta et al., 2020) . The dynamics of the vaccine immune responses and the duration of protection based on antibody titers are needed to be investigated. Here we set out an automated chemiluminescent immunoassay (CLIA) to replace micro neutralization test (MNT) to detect NAb levels.

In current studies, many methods of serological assays have been used to measure antibodies (Ainsworth et al., 2020) . The qualitative analysis includes enzyme-linked immunosorbent assays, lateral flow assays, western blot-based assays, and so on.

Also the quantitative analysis has been invented, the Abbott SARS-CoV-2 immunoglobulin (Ig) G assay detects anti-N IgG using a 2-step chemiluminescent microparticle immunoassay method with acridinium-labeled anti-human IgG (Bryan et al., 2020) . The DiaSorin SARS-CoV-2 IgG assay is also a 2-step chemiluminescent microparticle immunoassay targeting undisclosed epitopes in the SARS-CoV-2 S protein and uses an isoluminolconjugated anti-human IgG. The Roche Anti-SARS-CoV total antibody assay is a 2-step bridging electrochemiluminesent immunoassay using ruthenium-labeled and biotin-conjugated N protein. The Siemens SARS-CoV-2 total antibody assay is a 1-step bridging CLIA method that detects antibodies against the RBD, using acridinium and biotinylated S1 RBD (Muecksch et al., 2021) . Here, we use a CLIA method, in accordance with Siemens' method, to test the concentration of NAb against the RBD. As a result, the titers and concentration of NAb are in strong positive correlation both in convalescent and vaccine people.

In our study, the statistic data originated from healthy group (675 individuals), convalescent group (232 individuals) and vaccine group (860 individuals). Our method can distinguish these three groups by geometric mean concentration of NAb (P<0.05 respectively). Through comprehensive analysis of the experiment data and literatures, two methods were used to determine the cutoff value and borderline of NAb concentration. According to the method reported by Peterhoff, the cutoff value and the borderline ranges of NAb concentration were determined by healthy group data (Peterhoff et al., 2021) . In our study, the cutoff value and borderline ranges were validated by ROC curve which resulted from the data in vaccinees and convalescent patients. As a result, the ROC curve outperformed the method reported by Peterhoff (Peterhoff et al., 2021) . The ROC curve analysis indicated AUC=0.901(p<0.001), sensitivity 87.4%, and specificity 78.1%. It was much better than that reported by Matusali et al (Matusali et al., 2021) .

As titers and concentration kept non-linear relationship, several estimating methods were applied to build the mathematical model. The progressive linear fitting model and decision-making tree model had low absolute error, strong correlation and high R-squares. Therefore, both progressive linear fitting model and decision-making tree model were used to establish mathematical model and explore the relationship between titers and concentration of NAb. Also the transform values between titers and concentration can be mutually validated by two mathematical models.

According to our mathematical model analysis, we predicted that NAb concentration (Ibarrondo et al., 2020; Seow et al., 2020; Wajnberg et al., 2020) . As reported by Matusali et al, a neutralizing response was detected as soon as five days fso, and very high levels could be reached in the first weeks of symptoms. NAb could be detected up to 10 to 11 months fso, but quarter of individuals NAb titers declined (Matusali et al.,2021) . In muecksch's report, NAb titer decreased approximately 25%

per 2-week sampling interval, and decreased approximately 45% over 4 weeks (Muecksch et al., 2021) . It was similar to our study in both convalescent group and vaccine group.

It was observed that the convalescent people had higher titers than the vaccinees, which conforms to the immunological mechanism. The half-life period of NAb was twice longer in convalescent group. The protectiveness and effectiveness of NAb in convalescent group were much better than that in vaccine group. These findings may provide significant guide in clinical treatment and diagnosis. The chemiluminescent method may be used as a common test to measure the efficacy of vaccine, ensure the suitable therapeutic plasma and help to find people who have been infected by SARS-COV-2.

Combining all the information above, we can infer that it is practicable to use CLIA to replace MNT. As the CLIA is a fast, convenient and common method, it is possible to provide a common test for evaluating vaccine efficacy. The use of machine learning may also provide a new method for medical staff to study the clinical data and find the internal mechanism among various of clinical index.

Our study has some limitations. First, we did not get any other medical information, so we could not exclude irrespective factors which may have influence on the models. Second, because the COVID-19 pandemics was getting to an end in China, we were limited to get enough high NAb titers samples, which led to an influence on precision and accuracy in the mathematical model. Third, the sample size of convalescent people was not enough, so the results may have a deviation. Fourth, we did not collect the plasma after the first vaccination or half year after the second vaccination. Thus we could not analyze the dynamic change of neutralizing antibodies titers in vaccinees. Meanwhile we were not able to record the NAb titers of same convalescent people at different time (one month, three months, half year, one year, etc.). We believe the law of SARS-COV-2 neutralizing antibodies' dynamic change will come out with further study.

SARS-CoV-2 neutralizing antibody (NAb) is an essential biomarker to diagnose COVID-19 seroconversion and prognosis, also vaccine effectiveness. In our study, a CLIA method was set up to detect NAb automatically and estimate equivalence between NAb concentration tested by CLIA and NAb titers tested by MNT. Some mathematical models were established to evaluate the effectiveness, protectiveness and durability of vaccine. As our mathematical models predicted, SARS-CoV-2 vaccine-induced NAb durations do not exceed half year as yet. NAb protective 28 capabilities in vaccinee population are much lower than those in convalescent population. To enhance vaccinee people immunity anti SARS-CoV-2, it is necessary to inject three-pin vaccines to primarily immune people. Individuals who want to keep immune capability anti SARS-CoV-2 should inject vaccine each time per half-year.

NAb should be periodically tested for vaccine immunity.

Authors declare that they have no competing interests.

This work was supported by Shenzhen Medcaptain Medical Technology Co., Ltd. 

Transfusion of convalescent plasma for the early treatment of pneumonia in COVID-19 patients

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in

SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy

Serum Virus Neutralization Assay for Detection and Quantitation of Serum Neutralizing Antibodies to Influenza A Virus in Swine

COVID-19 Antibody Tests and Their Limitations

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19

Serology assays to manage COVID-19

Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples

SARS-CoV-2 serum neutralization assay: a traditional tool for a brand-new virus

Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients

Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the

Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a study protocol for a randomised controlled trial

Machine Learning methods for Quantitative Radiomic Biomarkers

A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization

A simple method of estimating fifty per cent endpoints

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection

Treatment of 5 critically ill patients with SARS-COV-2 with convalescent plasma

SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months

World Health Organization, Clinical management of COVID-19 patients: Living guidance

Neutralizing antibody responses to SARS-CoV-2 in a SARS-COV-2 convalescent patient cohort and their implications

Treatment with convalescent plasma for COVID-19 patients in Wuhan